Condition

Metastatic Prostate Neuroendocrine Carcinoma

ClinicalTrials.gov condition label

Clinical trials4

Recruiting2

Common interventions13

Lead sponsors shown4

Clinical trials

4 shown

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CTNCT06062745 · 2024-02-01

RECRUITING

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsNCT05691465 · 2023-12-27

RECRUITING

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerNCT04709276 · 2021-06-07

ACTIVE_NOT_RECRUITING

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerNCT04592237 · 2020-12-29

ACTIVE_NOT_RECRUITING

Common interventions

CabazitaxelDRUG2CarboplatinDRUG218F-fluciclovineDRUG1Biospecimen CollectionPROCEDURE1CetrelimabBIOLOGICAL1Computed TomographyPROCEDURE1Gallium Ga 68-DOTATATERADIATION1IpilimumabDRUG1Lutetium Lu 177 DotatateDRUG1NiraparibDRUG1NivolumabDRUG1PET/CTDEVICE1Positron Emission TomographyPROCEDURE1

Leading sponsors

Andrew J. Armstrong, MD1Brigham and Women's Hospital1M.D. Anderson Cancer Center1National Cancer Institute (NCI)1

Trial status mix

ACTIVE_NOT_RECRUITING2

RECRUITING2

Phase mix

PHASE23

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.